Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?

K. E. Earp (Lead / Corresponding author), B. W. Hancock, D. Short, R. A. Harvey, R. A. Fisher, D. Drew, N. Sarwar, J. A. Tidy, M. C. Winter, P. Chien, M. J. Seckl

Research output: Contribution to journalArticle

Abstract

Objective: To determine whether post-pregnancy human chorionic gonadotrophin screening after previous hydatidiform mole identifies patients with recurrent gestational trophoblastic disease. Study design: A retrospective evaluation of 9315 patients who underwent post-pregnancy screening from 2000 to 2009, as part of the National Gestational Trophoblastic Disease Service in the UK. Results: Patients with previous hydatidiform mole, who had human chorionic gonadotrophin screening after one or more subsequent pregnancies, were identified (n = 9315). Of these, 8630 patients had an initial hydatidiform mole that did not require chemotherapy. In 12,329 subsequent pregnancy events, screening with human chorionic gonadotrophin identified 3 cases of gestational trophoblastic neoplasm. The remaining 685 patients developed gestational trophoblastic neoplasm, following their initial hydatidiform mole and required chemotherapy. In this group there were 1012 further pregnancy events, human chorionic gonadotrophin screening identified 3 patients with gestational trophoblastic neoplasm. The overall recurrence rate was 6 in 13,341 events (risk 1: 2227). The rate was 3 in 12,329 (risk 1:4110) for HM that did not require chemotherapy and 3 in 1012 (1:337) for previously treated gestational trophoblastic neoplasm. All 6 patients with recurrent disease were successfully treated with chemotherapy. Conclusion: Routine post-pregnancy human chorionic gonadotrophin screening may be safely discontinued in patients with one previous uncomplicated hydatidiform mole.

Original languageEnglish
Pages (from-to)117-119
Number of pages3
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume234
Early online date6 Jan 2019
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Gestational Trophoblastic Disease
Hydatidiform Mole
Chorionic Gonadotropin
Pregnancy
Drug Therapy
Recurrence

Keywords

  • Gestational trophoblastic disease
  • Human chorionic gonadotrophin
  • Screening
  • Hydatidiform Mole/blood
  • Humans
  • Risk Factors
  • Postpartum Period/blood
  • Pregnancy
  • Chorionic Gonadotropin/blood
  • Gestational Trophoblastic Disease/diagnosis
  • Adult
  • Female
  • Retrospective Studies
  • Neoplasm Recurrence, Local/diagnosis
  • Uterine Neoplasms/blood

Cite this

Earp, K. E. ; Hancock, B. W. ; Short, D. ; Harvey, R. A. ; Fisher, R. A. ; Drew, D. ; Sarwar, N. ; Tidy, J. A. ; Winter, M. C. ; Chien, P. ; Seckl, M. J. / Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?. In: European Journal of Obstetrics Gynecology and Reproductive Biology. 2019 ; Vol. 234. pp. 117-119.
@article{2cfe03efb9314559a9287d3dc2054c7f,
title = "Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?",
abstract = "Objective: To determine whether post-pregnancy human chorionic gonadotrophin screening after previous hydatidiform mole identifies patients with recurrent gestational trophoblastic disease. Study design: A retrospective evaluation of 9315 patients who underwent post-pregnancy screening from 2000 to 2009, as part of the National Gestational Trophoblastic Disease Service in the UK. Results: Patients with previous hydatidiform mole, who had human chorionic gonadotrophin screening after one or more subsequent pregnancies, were identified (n = 9315). Of these, 8630 patients had an initial hydatidiform mole that did not require chemotherapy. In 12,329 subsequent pregnancy events, screening with human chorionic gonadotrophin identified 3 cases of gestational trophoblastic neoplasm. The remaining 685 patients developed gestational trophoblastic neoplasm, following their initial hydatidiform mole and required chemotherapy. In this group there were 1012 further pregnancy events, human chorionic gonadotrophin screening identified 3 patients with gestational trophoblastic neoplasm. The overall recurrence rate was 6 in 13,341 events (risk 1: 2227). The rate was 3 in 12,329 (risk 1:4110) for HM that did not require chemotherapy and 3 in 1012 (1:337) for previously treated gestational trophoblastic neoplasm. All 6 patients with recurrent disease were successfully treated with chemotherapy. Conclusion: Routine post-pregnancy human chorionic gonadotrophin screening may be safely discontinued in patients with one previous uncomplicated hydatidiform mole.",
keywords = "Gestational trophoblastic disease, Human chorionic gonadotrophin, Screening, Hydatidiform Mole/blood, Humans, Risk Factors, Postpartum Period/blood, Pregnancy, Chorionic Gonadotropin/blood, Gestational Trophoblastic Disease/diagnosis, Adult, Female, Retrospective Studies, Neoplasm Recurrence, Local/diagnosis, Uterine Neoplasms/blood",
author = "Earp, {K. E.} and Hancock, {B. W.} and D. Short and Harvey, {R. A.} and Fisher, {R. A.} and D. Drew and N. Sarwar and Tidy, {J. A.} and Winter, {M. C.} and P. Chien and Seckl, {M. J.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ejogrb.2018.12.029",
language = "English",
volume = "234",
pages = "117--119",
journal = "European Journal of Obstetrics & Gynecology and Reproductive Biology",
issn = "0301-2115",
publisher = "Elsevier",

}

Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease? / Earp, K. E. (Lead / Corresponding author); Hancock, B. W.; Short, D.; Harvey, R. A.; Fisher, R. A.; Drew, D.; Sarwar, N.; Tidy, J. A.; Winter, M. C.; Chien, P.; Seckl, M. J.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 234, 01.03.2019, p. 117-119.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?

AU - Earp, K. E.

AU - Hancock, B. W.

AU - Short, D.

AU - Harvey, R. A.

AU - Fisher, R. A.

AU - Drew, D.

AU - Sarwar, N.

AU - Tidy, J. A.

AU - Winter, M. C.

AU - Chien, P.

AU - Seckl, M. J.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objective: To determine whether post-pregnancy human chorionic gonadotrophin screening after previous hydatidiform mole identifies patients with recurrent gestational trophoblastic disease. Study design: A retrospective evaluation of 9315 patients who underwent post-pregnancy screening from 2000 to 2009, as part of the National Gestational Trophoblastic Disease Service in the UK. Results: Patients with previous hydatidiform mole, who had human chorionic gonadotrophin screening after one or more subsequent pregnancies, were identified (n = 9315). Of these, 8630 patients had an initial hydatidiform mole that did not require chemotherapy. In 12,329 subsequent pregnancy events, screening with human chorionic gonadotrophin identified 3 cases of gestational trophoblastic neoplasm. The remaining 685 patients developed gestational trophoblastic neoplasm, following their initial hydatidiform mole and required chemotherapy. In this group there were 1012 further pregnancy events, human chorionic gonadotrophin screening identified 3 patients with gestational trophoblastic neoplasm. The overall recurrence rate was 6 in 13,341 events (risk 1: 2227). The rate was 3 in 12,329 (risk 1:4110) for HM that did not require chemotherapy and 3 in 1012 (1:337) for previously treated gestational trophoblastic neoplasm. All 6 patients with recurrent disease were successfully treated with chemotherapy. Conclusion: Routine post-pregnancy human chorionic gonadotrophin screening may be safely discontinued in patients with one previous uncomplicated hydatidiform mole.

AB - Objective: To determine whether post-pregnancy human chorionic gonadotrophin screening after previous hydatidiform mole identifies patients with recurrent gestational trophoblastic disease. Study design: A retrospective evaluation of 9315 patients who underwent post-pregnancy screening from 2000 to 2009, as part of the National Gestational Trophoblastic Disease Service in the UK. Results: Patients with previous hydatidiform mole, who had human chorionic gonadotrophin screening after one or more subsequent pregnancies, were identified (n = 9315). Of these, 8630 patients had an initial hydatidiform mole that did not require chemotherapy. In 12,329 subsequent pregnancy events, screening with human chorionic gonadotrophin identified 3 cases of gestational trophoblastic neoplasm. The remaining 685 patients developed gestational trophoblastic neoplasm, following their initial hydatidiform mole and required chemotherapy. In this group there were 1012 further pregnancy events, human chorionic gonadotrophin screening identified 3 patients with gestational trophoblastic neoplasm. The overall recurrence rate was 6 in 13,341 events (risk 1: 2227). The rate was 3 in 12,329 (risk 1:4110) for HM that did not require chemotherapy and 3 in 1012 (1:337) for previously treated gestational trophoblastic neoplasm. All 6 patients with recurrent disease were successfully treated with chemotherapy. Conclusion: Routine post-pregnancy human chorionic gonadotrophin screening may be safely discontinued in patients with one previous uncomplicated hydatidiform mole.

KW - Gestational trophoblastic disease

KW - Human chorionic gonadotrophin

KW - Screening

KW - Hydatidiform Mole/blood

KW - Humans

KW - Risk Factors

KW - Postpartum Period/blood

KW - Pregnancy

KW - Chorionic Gonadotropin/blood

KW - Gestational Trophoblastic Disease/diagnosis

KW - Adult

KW - Female

KW - Retrospective Studies

KW - Neoplasm Recurrence, Local/diagnosis

KW - Uterine Neoplasms/blood

UR - http://www.scopus.com/inward/record.url?scp=85060307037&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2018.12.029

DO - 10.1016/j.ejogrb.2018.12.029

M3 - Article

VL - 234

SP - 117

EP - 119

JO - European Journal of Obstetrics & Gynecology and Reproductive Biology

JF - European Journal of Obstetrics & Gynecology and Reproductive Biology

SN - 0301-2115

ER -